OCX US68235C1071

Report

Delayed Nasdaq - 05/24 04:00:00 pm
0.9843	USD		-8.86%

05/24	Stephens Downgrades OncoCyte to Equalweight From Overweight, Adjusts Price Target to $1.25 From $2	MT
05/16	Piper Sandler Trims OncoCyte's Price Target to $1.40 From $1.80, Maintains Overweight Rating	MT
05/12	ONCOCYTE CORP Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ

News

Official Publications

Sector news

OncoCyte Strikes Deal with Thermo Fisher to Expand Access to Precision Oncology

01/18/2022 | 04:33pm EDT

Stocks mentioned in the article	Change	Last	1st jan.
ON SEMICONDUCTOR CORPORATION	-2.49%	54.5	-19.76%
ONCOCYTE CORPORATION	-8.86%	0.9843	-54.64%
THERMO FISHER SCIENTIFIC	-1.15%	548.82	-16.79%

All news about ONCOCYTE CORPORATION

05/24	Stephens Downgrades OncoCyte to Equalweight From Overweight, Adjusts Price Target to $1..	MT
05/16	Piper Sandler Trims OncoCyte's Price Target to $1.40 From $1.80, Maintains Overweight R..	MT
05/12	ONCOCYTE CORP Management's Discussion and Analysis of Financial Condition and Results ..	AQ
05/12	Needham Adjusts OncoCyte's Price Target to $2.25 From $4 on 'Peer Multiple Compression,..	MT
05/11	ONCOCYTE : Q1 Earnings Snapshot	AQ
05/11	TRANSCRIPT : OncoCyte Corporation, Q1 2022 Earnings Call, May 11, 2022	CI
05/11	ONCOCYTE CORP : Results of Operations and Financial Condition, Change in Directors or Prin..	AQ
05/11	OncoCyte Corporation Reports Earnings Results for the First Quarter Ended March 31, 202..	CI
05/11	Oncocyte Reports First Quarter 2022 Financial Results	AQ
05/11	Earnings Flash (OCX) ONCOCYTE CORPORATION Posts Q1 Revenue $1.4M	MT

More news

Analyst Recommendations on ONCOCYTE CORPORATION

05/24	Stephens Downgrades OncoCyte to Equalweight From Overweight, Adjusts Price Target to $1..	MT
05/16	Piper Sandler Trims OncoCyte's Price Target to $1.40 From $1.80, Maintains Overweight R..	MT
05/12	Needham Adjusts OncoCyte's Price Target to $2.25 From $4 on 'Peer Multiple Compression,..	MT

More recommendations

Financials (USD)

Sales 2022	9,30 M - -
Net income 2022	-50,8 M - -
Net Debt 2022	- - -
P/E ratio 2022	-2,01x
Yield 2022	-

Capitalization	121 M 121 M -
Capi. / Sales 2022	13,0x
Capi. / Sales 2023	5,79x
Nbr of Employees	113
Free-Float	91,9%

More Financials

Chart ONCOCYTE CORPORATION

Duration : Period :

OncoCyte Corporation Technical Analysis Chart | OCX | US68235C1071 | MarketScreener

Full-screen chart

Income Statement Evolution

More Financials

Consensus

Sell Buy
Mean consensus	OUTPERFORM
Number of Analysts	7
Last Close Price	0,98 $
Average target price	3,15 $
Spread / Average Target	220%

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Ronald Asbury Andrews	President, Chief Executive Officer & Director
Mitchell Stuart Levine	Chief Financial Officer
Andrew Arno	Chairman
Douglas T. Ross	Chief Science Officer
Ekkehard Schütz	Chief Technology Officer

More about the company

Sector and Competitors

		1st jan.	Capi. (M$)
	ONCOCYTE CORPORATION	-54.64%	121


GILEAD SCIENCES, INC.	-11.38%	79 850
REGENERON PHARMACEUTICALS, INC.	8.63%	73 473
VERTEX PHARMACEUTICALS	22.26%	68 632
WUXI APPTEC CO., LTD.	-22.20%	42 378
BIONTECH SE	-36.69%	39 666

More Results

ONCOCYTE CORPORATION

OncoCyte Strikes Deal with Thermo Fisher to Expand Access to Precision Oncology

Send by mail :